{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:14:04Z","timestamp":1791335644226,"version":"4.3.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["NET-2016-02361632"],"award-info":[{"award-number":["NET-2016-02361632"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["NET-2016-02361632"],"award-info":[{"award-number":["NET-2016-02361632"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC","doi-asserted-by":"crossref","award":["ID.21073"],"award-info":[{"award-number":["ID.21073"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC","doi-asserted-by":"crossref","award":["ID.21073"],"award-info":[{"award-number":["ID.21073"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC","doi-asserted-by":"crossref","award":["ID.21073"],"award-info":[{"award-number":["ID.21073"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC","doi-asserted-by":"crossref","award":["ID.21073"],"award-info":[{"award-number":["ID.21073"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Co-targeting of immune checkpoint inhibitors (ICI) CTLA-4 and PD-1 has recently become the new first-line standard of care therapy of pleural mesothelioma (PM) patients, with a significant improvement of overall survival (OS) over conventional chemotherapy. The analysis by tumor histotype demonstrated greater efficacy of ICI therapy compared to standard chemotherapy in non-epithelioid (non-E)\n                      <jats:italic>vs.<\/jats:italic>\n                      epithelioid (E) PM, although some E PM patients also benefit from ICI treatment. This evidence suggests that molecular tumor features, beyond histotype, could be relevant to improve the efficacy of ICI therapy in PM. Among these, tumor DNA methylation emerges as a promising factor to explore, due to its potential role in driving the immune phenotype of cancer cells. Therefore, we utilized a panel of cultured PM cells of different histotype to provide preclinical evidence supporting the role of the tumor methylation landscape, along with its pharmacologic modulation, to prospectively improve the efficacy of ICI therapy of PM patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The methylome profile (EPIC array) of distinct E (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095) and non-E (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099) PM cell lines was analyzed, followed by integrated analysis with their associated transcriptomic profile (Clariom S array), before and after in vitro treatment with the DNA hypomethylating agent (DHA) guadecitabine. The most variable methylated probes were selected to calculate the methylation score (CIMP index) for each cell line at baseline. Genes that were differentially expressed (DE) and differentially methylated (DM) were then selected for gene ontology analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The CIMP index stratified PM cell lines into two distinct classes, CIMP (hyper-methylated;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097) and LOW (hypo-methylated;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097), regardless of their E or non-E histotype. Integrated methylome and transcriptome analyses revealed that CIMP PM cells exhibited a substantial number of hyper-methylated, silenced genes, which negatively impacted their immune phenotype compared to LOW PM cells.\n                    <\/jats:p>\n                    <jats:p>Treatment with DHA reverted the methylation-driven immune-compromised profile of CIMP PM cells and enhanced the constitutive immune-favorable profile of LOW PM cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study highlighted the relevance of DNA methylation in shaping the constitutive immune classification of PM cells, independent of their histological subtypes. The identified role of DHA in shifting the phenotype of PM cells towards an immune-favorable state highlights its potential for evaluation in phase I\/II clinical trials investigating the efficacy of epigenetic-based ICI combinations to reverse cancer immune resistance mechanisms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03310-0","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:38:53Z","timestamp":1739839133000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy"],"prefix":"10.1186","volume":"44","author":[{"given":"Maria Fortunata","family":"Lofiego","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Tufano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Solmonese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Marzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Piazzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Celesti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Pia","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa Maria Rosaria","family":"Noviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Mortarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Anichini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ceccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Coral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Di Giacomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Covre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the EPigenetic Immune-oncology Consortium Airc (EPICA) investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"3310_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3389\/fonc.2019.00078","volume":"9","author":"JG Zhou","year":"2019","unstructured":"Zhou JG, Zhong H, Zhang J, Jin SH, Roudi R, Ma H. Development and Validation of a Prognostic Signature for Malignant Pleural Mesothelioma. Front Oncol. 2019;9:78.","journal-title":"Front Oncol"},{"issue":"1","key":"3310_CR2","doi-asserted-by":"publisher","first-page":"7056","DOI":"10.1038\/s41467-023-42668-7","volume":"14","author":"J Chiaro","year":"2023","unstructured":"Chiaro J, Antignani G, Feola S, Feodoroff M, Martins B, Cojoc H, et al. Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors. Nat Commun. 2023;14(1):7056.","journal-title":"Nat Commun"},{"issue":"11","key":"3310_CR3","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","volume":"14","author":"L Calabr\u00f2","year":"2013","unstructured":"Calabr\u00f2 L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2013;14(11):1104\u201311.","journal-title":"Lancet Oncol"},{"issue":"4","key":"3310_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","volume":"3","author":"L Calabr\u00f2","year":"2015","unstructured":"Calabr\u00f2 L, Morra A, Fonsatti E, Cutaia O, Fazio C, Annesi D, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med. 2015;3(4):301\u20139.","journal-title":"Lancet Respir Med"},{"issue":"9","key":"3310_CR5","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","volume":"18","author":"M Maio","year":"2017","unstructured":"Maio M, Scherpereel A, Calabr\u00f2 L, Aerts J, Perez SC, Bearz A, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18(9):1261\u201373.","journal-title":"Lancet Oncol"},{"issue":"10272","key":"3310_CR6","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet. 2021;397(10272):375\u201386.","journal-title":"The Lancet"},{"issue":"5","key":"3310_CR7","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","volume":"33","author":"S Peters","year":"2022","unstructured":"Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022;33(5):488\u201399.","journal-title":"Ann Oncol"},{"issue":"4","key":"3310_CR8","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3390\/ijms19041041","volume":"19","author":"J Minnema-Luiting","year":"2018","unstructured":"Minnema-Luiting J, Vroman H, Aerts J, Cornelissen R. Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma. IJMS. 2018;19(4):1041.","journal-title":"IJMS"},{"issue":"1","key":"3310_CR9","doi-asserted-by":"publisher","first-page":"2308097","DOI":"10.1080\/15384047.2024.2308097","volume":"25","author":"GS Santiago-S\u00e1nchez","year":"2024","unstructured":"Santiago-S\u00e1nchez GS, Fabian KP, Hodge JW. A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance. Cancer Biol Ther. 2024;25(1):2308097.","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"3310_CR10","doi-asserted-by":"publisher","first-page":"e001601","DOI":"10.1136\/jitc-2020-001601","volume":"9","author":"A Alay","year":"2021","unstructured":"Alay A, Cordero D, Hijazo-Pechero S, Aliagas E, Lopez-Doriga A, Mar\u00edn R, et al. Integrative transcriptome analysis of malignant pleural mesothelioma reveals a clinically relevant immune-based classification. J Immunother Cancer. 2021;9(2):e001601.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"3310_CR11","doi-asserted-by":"publisher","first-page":"5786","DOI":"10.3390\/ijms23105786","volume":"23","author":"L Mannarino","year":"2022","unstructured":"Mannarino L, Paracchini L, Pezzuto F, Olteanu GE, Moracci L, Vedovelli L, et al. Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study. IJMS. 2022;23(10):5786.","journal-title":"IJMS"},{"issue":"1","key":"3310_CR12","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s41467-019-09307-6","volume":"10","author":"Y Blum","year":"2019","unstructured":"Blum Y, Meiller C, Quetel L, Elarouci N, Ayadi M, Tashtanbaeva D, et al. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nat Commun. 2019;10(1):1333.","journal-title":"Nat Commun"},{"key":"3310_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13148-024-01633-x","volume":"16","author":"D Zhu","year":"2024","unstructured":"Zhu D, Zeng S, Su C, et al. The interaction between DNA methylation and tumor immune microenvironment: from the laboratory to clinical applications. Clin Epigenet. 2024;16:24. https:\/\/doi.org\/10.1186\/s13148-024-01633-x.","journal-title":"Clin Epigenet"},{"key":"3310_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41416-023-02292-0","volume":"129","author":"F Zhong","year":"2023","unstructured":"Zhong F, Lin Y, Zhao L, et al. Reshaping the tumour immune microenvironment in solid tumours via tumour cell and immune cell DNA methylation: from mechanisms to therapeutics. Br J Cancer. 2023;129:24\u201337. https:\/\/doi.org\/10.1038\/s41416-023-02292-0.","journal-title":"Br J Cancer"},{"issue":"18","key":"3310_CR15","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1158\/1078-0432.CCR-14-2914","volume":"21","author":"M Maio","year":"2015","unstructured":"Maio M, Covre A, Fratta E, Di Giacomo AM, Taverna P, Natali PG, et al. Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy. Clin Cancer Res. 2015;21(18):4040\u20137.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3310_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/epigenomes5040027","volume":"5","author":"MF Lofiego","year":"2021","unstructured":"Lofiego MF, Cannito S, Fazio C, Piazzini F, Cutaia O, Solmonese L, et al. Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy. Epigenomes. 2021;5(4):27.","journal-title":"Epigenomes"},{"issue":"1","key":"3310_CR17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s13046-022-02529-5","volume":"41","author":"A Anichini","year":"2022","unstructured":"Anichini A, Molla A, Nicolini G, Perotti VE, Sgambelluri F, Covre A, et al. Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy. J Exp Clin Cancer Res. 2022;41(1):325.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3310_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12967-024-05040-x","volume":"22","author":"MF Lofiego","year":"2024","unstructured":"Lofiego MF, Piazzini F, Caruso FP, Marzani F, Solmonese L, Bello E, et al. Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches. J Transl Med. 2024;22(1):223.","journal-title":"J Transl Med"},{"issue":"1","key":"3310_CR19","doi-asserted-by":"publisher","first-page":"5914","DOI":"10.1038\/s41467-023-40994-4","volume":"14","author":"TMR Noviello","year":"2023","unstructured":"Noviello TMR, Di Giacomo AM, Caruso FP, Covre A, Mortarini R, Scala G, et al. Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial. Nat Commun. 2023;14(1):5914.","journal-title":"Nat Commun"},{"issue":"6","key":"3310_CR20","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/sj.bjc.6600174","volume":"86","author":"L Sigalotti","year":"2002","unstructured":"Sigalotti L, Coral S, Altomonte M, Natali L, Gaudino G, Cacciotti P, et al. Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Br J Cancer. 2002;86(6):979\u201382.","journal-title":"Br J Cancer"},{"issue":"1","key":"3310_CR21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/modpathol.2011.144","volume":"25","author":"A Fassina","year":"2012","unstructured":"Fassina A, Cappellesso R, Guzzardo V, Dalla Via L, Piccolo S, Ventura L, et al. Epithelial\u2013mesenchymal transition in malignant mesothelioma. Mod Pathol. 2012;25(1):86\u201399.","journal-title":"Mod Pathol"},{"issue":"7","key":"3310_CR22","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/bjc.2012.361","volume":"107","author":"S Coral","year":"2012","unstructured":"Coral S, Covre A, Jmg Nicolay H, Parisi G, Rizzo A, Colizzi F, et al. Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications. Br J Cancer. 2012;107(7):1116\u201324.","journal-title":"Br J Cancer"},{"key":"3310_CR23","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3389\/fphar.2018.01443","volume":"9","author":"C Fazio","year":"2018","unstructured":"Fazio C, Covre A, Cutaia O, Lofiego MF, Tunici P, Chiarucci C, et al. Immunomodulatory properties of DNA hypomethylating agents: selecting the optimal epigenetic partner for cancer immunotherapy. Front Pharmacol. 2018;9:1443.","journal-title":"Front Pharmacol"},{"issue":"11","key":"3310_CR24","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1186\/s13059-014-0503-2","volume":"15","author":"JP Fortin","year":"2014","unstructured":"Fortin JP, Labbe A, Lemire M, Zanke BW, Hudson TJ, Fertig EJ, et al. Functional normalization of 450k methylation array data improves replication in large cancer studies. Genome Biol. 2014;15(11):503.","journal-title":"Genome Biol"},{"issue":"10","key":"3310_CR25","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/bioinformatics\/btu049","volume":"30","author":"MJ Aryee","year":"2014","unstructured":"Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics. 2014;30(10):1363\u20139.","journal-title":"Bioinformatics"},{"issue":"7","key":"3310_CR26","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47\u2013e47.","journal-title":"Nucleic Acids Res"},{"key":"3310_CR27","doi-asserted-by":"crossref","unstructured":"Phipson B, Lee S, Majewski IJ, Alexander WS, Smyth GK. Robust hyperparameter estimation protects against hypervariable genes and improves power to detect differential expression. Ann Appl Stat. 2016;10(2). Available from: https:\/\/projecteuclid.org\/journals\/annals-of-applied-statistics\/volume-10\/issue-2\/Robust-hyperparameter-estimation-protects-against-hypervariable-genes-and-improves-power\/10.1214\/16-AOAS920.full. Cited 2024 Nov 28.","DOI":"10.1214\/16-AOAS920"},{"issue":"4","key":"3310_CR28","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","volume":"30","author":"A Kr\u00e4mer","year":"2014","unstructured":"Kr\u00e4mer A, Green J, Pollard J, Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics. 2014;30(4):523\u201330.","journal-title":"Bioinformatics"},{"issue":"W1","key":"3310_CR29","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44(W1):W90\u20137.","journal-title":"Nucleic Acids Res"},{"key":"3310_CR30","doi-asserted-by":"crossref","unstructured":"Silva TC, Colaprico A, Olsen C, D\u2019Angelo F, Bontempi G, Ceccarelli M, et al. TCGA Workflow: Analyze cancer genomics and epigenomics data using Bioconductor packages. F1000Res. 2016;5:1542.","DOI":"10.12688\/f1000research.8923.1"},{"issue":"3","key":"3310_CR31","first-page":"100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innov. 2021;2(3):100141.","journal-title":"Innov."},{"issue":"1","key":"3310_CR32","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17(1):218.","journal-title":"Genome Biol"},{"issue":"2","key":"3310_CR33","doi-asserted-by":"publisher","first-page":"e1253654","DOI":"10.1080\/2162402X.2016.1253654","volume":"6","author":"W Hendrickx","year":"2017","unstructured":"Hendrickx W, Simeone I, Anjum S, Mokrab Y, Bertucci F, Finetti P, et al. Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. OncoImmunology. 2017;6(2):e1253654.","journal-title":"OncoImmunology"},{"issue":"10","key":"3310_CR34","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/s41591-018-0157-9","volume":"24","author":"N Auslander","year":"2018","unstructured":"Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat Med. 2018;24(10):1545\u20139.","journal-title":"Nat Med"},{"issue":"4","key":"3310_CR35","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/s41416-020-01145-4","volume":"124","author":"T Turan","year":"2021","unstructured":"Turan T, Kongpachith S, Halliwill K, Roelands J, Hendrickx W, Marincola FM, et al. A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival. Br J Cancer. 2021;124(4):760\u20139.","journal-title":"Br J Cancer"},{"issue":"5","key":"3310_CR36","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","volume":"162","author":"KB Chiappinelli","year":"2015","unstructured":"Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 2015;162(5):974\u201386.","journal-title":"Cell"},{"issue":"4","key":"3310_CR37","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.ccell.2020.08.005","volume":"38","author":"CS Grasso","year":"2020","unstructured":"Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, et al. Conserved Interferon-\u03b3 Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer Cell. 2020;38(4):500-515.e3.","journal-title":"Cancer Cell"},{"issue":"1","key":"3310_CR38","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.cell.2023.11.037","volume":"187","author":"J Pozniak","year":"2024","unstructured":"Pozniak J, Pedri D, Landeloos E, Van Herck Y, Antoranz A, Vanwynsberghe L, et al. A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma. Cell. 2024;187(1):166-183.e25.","journal-title":"Cell"},{"issue":"8","key":"3310_CR39","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade. J Clin Investig. 2017;127(8):2930\u201340.","journal-title":"J Clin Investig"},{"key":"3310_CR40","doi-asserted-by":"crossref","unstructured":"Orozco Morales ML, Rinaldi CA, De Jong E, Lansley SM, Gummer JPA, Olasz B, et al. PPAR\u03b1 and PPAR\u03b3 activation is associated with pleural mesothelioma invasion but therapeutic inhibition is ineffective. iScience. 2021;25(1):103571.","DOI":"10.1016\/j.isci.2021.103571"},{"issue":"4","key":"3310_CR41","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41588-023-01321-1","volume":"55","author":"L Mangiante","year":"2023","unstructured":"Mangiante L, Alcala N, Sexton-Oates A, Di Genova A, Gonzalez-Perez A, Khandekar A, et al. Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity. Nat Genet. 2023;55(4):607\u201318.","journal-title":"Nat Genet"},{"issue":"7","key":"3310_CR42","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.3390\/cancers13071660","volume":"13","author":"KB Karunakaran","year":"2021","unstructured":"Karunakaran KB, Yanamala N, Boyce G, Becich MJ, Ganapathiraju MK. Malignant Pleural Mesothelioma Interactome with 364 Novel Protein-Protein Interactions. Cancers (Basel). 2021;13(7):1660.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"3310_CR43","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1159\/000341476","volume":"30","author":"H Okuwa","year":"2012","unstructured":"Okuwa H, Kanno T, Fujita Y, Gotoh A, Tabata C, Fukuoka K, et al. Sphingosine Suppresses Mesothelioma Cell Proliferation by Inhibiting PKC-d and Inducing Cell Cycle Arrest at the G0 \/G1 Phase. Cell Physiol Biochem. 2012;30(4):995\u20131004.","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"3310_CR44","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13073-024-01318-3","volume":"16","author":"Q Qin","year":"2024","unstructured":"Qin Q, Zhou Y, Guo J, Chen Q, Tang W, Li Y, et al. Conserved methylation signatures associate with the tumor immune microenvironment and immunotherapy response. Genome Med. 2024;16(1):47.","journal-title":"Genome Med"},{"issue":"9","key":"3310_CR45","doi-asserted-by":"publisher","first-page":"e002671","DOI":"10.1136\/jitc-2021-002671","volume":"9","author":"Q Zou","year":"2021","unstructured":"Zou Q, Wang X, Ren D, Hu B, Tang G, Zhang Y, et al. DNA methylation-based signature of CD8+ tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer. J Immunother Cancer. 2021;9(9):e002671.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"3310_CR46","doi-asserted-by":"publisher","first-page":"2192894","DOI":"10.1080\/15592294.2023.2192894","volume":"18","author":"C Zhang","year":"2023","unstructured":"Zhang C, Sheng Q, Zhao N, Huang S, Zhao Y. DNA hypomethylation mediates immune response in pan-cancer. Epigenetics. 2023;18(1):2192894.","journal-title":"Epigenetics"},{"key":"3310_CR47","doi-asserted-by":"publisher","first-page":"114791","DOI":"10.1016\/j.ejmech.2022.114791","volume":"244","author":"X Tian","year":"2022","unstructured":"Tian X, Xu F, Zhu Q, Feng Z, Dai W, Zhou Y, et al. Medicinal chemistry perspective on cGAS-STING signaling pathway with small molecule inhibitors. Eur J Med Chem. 2022;244:114791.","journal-title":"Eur J Med Chem"},{"issue":"6588","key":"3310_CR48","doi-asserted-by":"publisher","first-page":"eabk3112","DOI":"10.1126\/science.abk3112","volume":"376","author":"SJ Hoyt","year":"2022","unstructured":"Hoyt SJ, Storer JM, Hartley GA, Grady PGS, Gershman A, de Lima LG, et al. From telomere to telomere: the transcriptional and epigenetic state of human repeat elements. Science. 2022;376(6588):eabk3112.","journal-title":"Science."},{"issue":"7957","key":"3310_CR49","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41586-023-05771-9","volume":"616","author":"KW Ng","year":"2023","unstructured":"Ng KW, Boumelha J, Enfield KSS, Almagro J, Cha H, Pich O, et al. Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Nature. 2023;616(7957):563\u201373.","journal-title":"Nature"},{"key":"3310_CR50","doi-asserted-by":"crossref","unstructured":"Chen R, Ishak CA, De Carvalho DD. Endogenous retroelements and the viral mimicry response in cancer therapy and cellular homeostasis. Cancer Discov. 2021 Nov;11(11):2707\u20132725.51.Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 2016;164(5):1073.","DOI":"10.1158\/2159-8290.CD-21-0506"},{"issue":"12","key":"3310_CR51","doi-asserted-by":"publisher","first-page":"100430","DOI":"10.1016\/j.jtocrr.2022.100430","volume":"3","author":"S Sun","year":"2022","unstructured":"Sun S, Qi W, Rehrauer H, Ronner M, Hariharan A, Wipplinger M, et al. Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma. JTO Clinical and Research Reports. 2022;3(12):100430.","journal-title":"JTO Clinical and Research Reports"},{"issue":"7","key":"3310_CR52","doi-asserted-by":"publisher","first-page":"e98575","DOI":"10.1172\/jci.insight.98575","volume":"3","author":"HS Lee","year":"2018","unstructured":"Lee HS, Jang HJ, Choi JM, Zhang J, De Rosen VL, Wheeler TM, et al. Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma. JCI Insight. 2018;3(7):e98575.","journal-title":"JCI Insight"},{"issue":"10","key":"3310_CR53","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.2217\/imt.12.108","volume":"4","author":"R Cornelissen","year":"2012","unstructured":"Cornelissen R, Lievense LA, Heuvers ME, Maat AP, Hendriks RW, Hoogsteden HC, et al. Dendritic Cell-Based Immunotherapy in Mesothelioma. Immunotherapy. 2012;4(10):1011\u201322.","journal-title":"Immunotherapy"},{"issue":"8","key":"3310_CR54","first-page":"742","volume":"4","author":"W Anani","year":"2011","unstructured":"Anani W, Bruggeman R, Zander DS. \u03b2-catenin expression in benign and malignant pleural disorders. Int J Clin Exp Pathol. 2011;4(8):742\u20137.","journal-title":"Int J Clin Exp Pathol"},{"issue":"10","key":"3310_CR55","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","volume":"25","author":"JJ Luke","year":"2019","unstructured":"Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF. WNT\/\u03b2-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clin Cancer Res. 2019;25(10):3074\u201383.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3310_CR56","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.ccell.2016.05.005","volume":"29","author":"F Zanconato","year":"2016","unstructured":"Zanconato F, Cordenonsi M, Piccolo S. YAP\/TAZ at the Roots of Cancer. Cancer Cell. 2016;29(6):783\u2013803.","journal-title":"Cancer Cell"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03310-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03310-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03310-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:38:59Z","timestamp":1739839139000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03310-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3310"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03310-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.08.08.607174","asserted-by":"object"}]},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"24 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AMDG has served as consultant and\/or advisor to Incyte, Pierre Fabre, Glaxo Smith Kline, Bristol-Myers Squibb, Merck Sharp Dohme, and Sanofi and has received compensated educational activities from Bristol Myers Squibb, Merck Sharp Dohme, Pierre Fabre and Sanofi. MM has served as consultant and\/or advisor to Roche, Bristol-Myers Squibb, Merck Sharp Dohme, Incyte, AstraZeneca, Amgen, Pierre Fabre, Eli Lilly, Glaxo Smith Kline, Sciclone, Sanofi, Alfasigma, and Merck Serono; and owns shares in Theravance and Epigen Therapeutics Srl. MC serves as consultant and\/or advisor to Moderna Therapeutics and is founder and owns shares of Immunomica srl. AC and SC own shares in Epigen Therapeutics Srl. Other authors have nothing to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}